Potential of Varicella zoster virus thymidine kinase as a suicide gene in breast cancer cells

Gene Therapy

Volumn 4, Issue 6, 1997, Pages 560-569

  Grignet Debrus, C ^a   Calberg Bacq, C M ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Breast cancer; BVDU ((E) 5 (2 bromovinyl) 2' deoxyuridine); Cancer gene therapy; Thymidine kinase; Varicella zoster virus

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR; THYMIDINE KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; GENE TRANSFER; GLIOSARCOMA; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RETROVIRUS; SUICIDE GENE; VARICELLA ZOSTER VIRUS; VIRUS GENE;

HUMAN HERPESVIRUS 3; MUS MUSCULUS; UNIDENTIFIED RETROVIRUS;

EID: 0030758623     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300435     Document Type: Article

References (60)

1. Moolten FL. Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279-287
2. Deonarain MP, Spooner RA, Epenetos AA. Genetic delivery of enzymes for cancer therapy. Gene Therapy 1995; 2: 235-244.
3. Moolten FL. Tumor chemosensitivity conferred by inserted Herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
4. Field AK et al 9-{(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl} guanine. a selective inhibitor of Herpes group virus replication. Proc Natl Acad Sci USA 1983; 80: 4139-1143.
5. Mar E-C, Chiou J-F, Cheng Y-C, Huang E-S. Inhibition of cellular DNA polymerase α and human cytomegalovirus-induced DNA polymerase by triphosphates of 9-(2-hydroxy-ethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxy-methyl)guanine. J Virol 1985, 53: 776-780.
6. Ezzedine ZD et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the Herpes simplex virus thymidine kinase gene. New Biol 1991; 3: 608-614.
7. Moolten FL, Wells JM. Curability of tumors bearing Herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300.
8. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
9. Ram Z et al. In situ retrovirus-mediated gene transfer for the treament of brain tumors in rats. Cancer Res 1993; 53: 83-88.
10. Cool V et al. Curative potential of Herpes simplex virus thymidine kinase gene transfer in rats with 9L gliosarcoma. Hum Gene Ther 1996; 7. 627-635.
11. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
12. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
13. Mesnil M et al. Bystander killing of cancer cells by Herpes simplex virus thymidine kinase is mediated by connexins. Proc Natl Acad Sci USA 1996; 93: 1831-1835.
14. Elshami AA et al. Gap junctions play a role in the bystander effect of the Herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Therapy 1996; 3: 85-92.
15. Samejima Y, Meruelo D. 'Bystander killing' induces apoptosis and is inhibited by forskolin. Gene Therapy 1995; 2: 50-58.
16. Ram Z et al. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg 1994; 81: 256-260.
17. Caruso M et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90: 7024-7028
18. Tapscott SJ et al. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc Natl Acad Sci USA 1994; 91: 8185-8189.
19. Gagandeep S et al. Prodrug-activated gene therapy: involvement of an immunological component in the 'bystander effect'. Cancer Gene Ther 1996; 3: 83-88.
20. Manome Y et al. Enhancer sequences of the DF3 gene regulate expression of the Herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res 1994; 54 5408-5413.
21. Link CJ, Kolb EM, Mulddon RR. Preliminary in vitro efficacy and toxicities studies of the Herpes simplex thymidine kinase gene system for the treatment of breast cancer. Hybridoma 1995; 14: 143-147.
22. Chen L et al. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 1995; 96: 2775-2782.
23. Yee D et al. Adenovirus-mediated gene transfer of Herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum Gene Ther 1996; 7: 1251-1257.
24. Sawyer MH et al. Molecular analysis of the pyrimidine deoxyribonucleoside kinase gene of wild-type and acyclovir-resistant strains of Varicella zoster virus. J Gen Virol 1988; 69: 2585-2593.
25. Averett DR et al. 6-Methoxypurine arabinoside as a selective and potent inhibitor of Varicella zoster virus. Antimicrob Agents Chemother 1991; 35: 851-857.
26. Balzarini J, Bohman C, De Clercq E. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of Herpes simplex virus type 1 or type 2. J Biol Chem 1993; 268: 6332-6337.
27. Cheng Y-C et al. Differential affinities of 5-(2-halogenovinyl)-2′-deoxyuridines for deoxythymidine kinases of various origins. Mol Pharmacol 1981; 20: 230-233.
28. Fyfe JA et al Thymidine kinase from Herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxy-ethoxymethyl)guanine. J Biol Chem 1978; 253: 8721-8727.
29. Roberts GB et al. Varicella zoster virus thymidine kinase. Characterization and substrate specificity. Biochem Pharmacol 1993; 46: 2209-2218.
30. Elion GB et al. Selectivity of action of an antiherpetic agent, 9(2-hydroxyethoxymethyl)guanine. Proc Natl Acad Sci USA 1977; 74: 5716-5720.
31. Hasegawa Y, Emi N, Shimokata K. Retroviral transfer of HSV1-TK gene into human lung cancer cell line. J Mol Med 1995; 73: 107-112.
32. De Clercq E et al. (E)-5-(2-bromovinyl)-2′-deoxyuridine: a potent and selective antiherpes agent. Proc Natl Acad Sci USA 1979; 76: 2947-2951.
33. Andrei G et al. Comparative activity of selected antiviral compounds against clinical isolates of Varicella zoster virus. Eur J Clin Microbiol Infect Dis 1995; 14: 318-328.
34. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239-4242.
35. Pelleher J, Sonenberg N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 1988; 334: 320-325.
36. Adam MA, Ramesh N, Miller AD, Osborne WRA. Internal initiation of translation in retroviral vectors carrying picornavirus 5′ nontranslated regions. J Virol 1991; 65: 4985-4990.
37. Ghattas IR, Sanes JR, Majors JE. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol Cell Biol 1991; 11: 5848-5859.
38. Morgan RA et al. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res 1992; 20: 1293-1299.
39. Mountford PS, Smith AG. Internal ribosome entry sites and dicistronic RNAs in mammalian transgenesis. Trends Genet 1995; 11: 179-184.
40. Price J, Turner D, Cepko C. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci USA 1987; 84: 156-160.
41. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167: 400-406.
42. Sugimoto Y et al. Retroviral coexpression of a multidrug resistance gene (MDR1) and human α-galactosidase A for gene therapy of Fabry disease. Hum Gene Ther 1995; 6: 905-915.
43. Kit S. Thymidine kinase. Microbiol Sci 1985; 2: 369-375.
44. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990; 50: 717-721.
45. Abina MA et al. LacZ gene transfer into tumor cells abrogates tumorigenicity and protects mice against the development of further tumors. Gene Therapy 1996; 3: 212-216.
46. Park N-H, Pavan-Langston D, De Clercq E. Efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine in the treatment of experimental Herpes simplex virus encephalitis in mice. Antiviral Res 1983; 3: 7-15.
47. Fick J et al. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA 1995; 92: 11071-11075.
48. Balzarini J, De Clercq E. 5-Substituted 2′-deoxyuridines: correlation between inhibition of tumor cell growth and inhibition of thymidine kinase and thymidylate synthetase. Biochem Pharmacol 1982; 31: 3673-3682.
49. Bohman C et al. Mechanism of cytostatic action of novel 5-(Thien-2-yl)- and 5-(Furan-2-yl)-substituted pyrimidine nucleoside analogues against tumor cells transfected by the thymidine kinase gene of Herpes simplex virus. J Biol Chem 1994; 269: 8036-8043.
50. Huber BE, Richards CA, Krenitsky TA. Retrovirus-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 1991; 88: 8039-8043.
51. Ido A et al. Gene therapy for hepatoma cells using a retrovirus vector carrying Herpes simplex virus thymidine kinase gene under the control of human α-fetoprotein gene promoter. Cancer Res 1995, 55: 3105-3109.
52. Balzarini J, Bohman C, Walker RT, De Clercq E. Comparative cytostatic activity of different antiherpetic drugs against Herpes simplex virus thymidine kinase gene-transfected tumor cells. Mol Pharmacol 1994; 45: 1253-1258.
53. Mullen CA, Coale MM, Lowe R, Blaese RM. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild-type tumor. Cancer Res 1994; 54: 1503-1506.
54. Trinh QT et al. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 1995; 55: 4808-4812.
55. Lee SW et al. Transcriptional downregulation of gap-junction proteins blocks junctional communication in human mammary tumor cell lines. J Cell Biol 1992; 118: 1213-1221.
56. Davison AJ, Scott JE. The complete DNA sequence of Varicella zoster virus. J Gen Virol 1986; 67: 1759-1816.
57. Jackson RJ, Howell MT, Kaminski A. The novel mechanism of initiation of picornavirus RNA translation. Trends Biochem Sci 1990; 15: 477-483.
58. Sambrook J, Fritsch EF, Maniatis T. Assay for β-galactosidase in extracts of mannmalian cells. In: Molecular Cloning: A Laboratory Manual. 2nd edn. Cold Spring Harbor Laboratory Press: New York, 1989, pp 16.66-16.67.
59. Sanes JR, Rubenstein JLR, Nicolas JF. Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos. EMBO J 1986; 5: 3133-3142.
60. Debrus S et al. Varicella zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency. J Virol 1995; 69: 3240-3245.